

## Chapter 9

# Diagnostic Approach to Myeloid Neoplasms With Predominantly Ineffective Hematopoiesis: AML, MDS, and MDS/MPNs

### ABSTRACT

*Acute myeloid leukemia, myelodysplastic syndromes, and myelodysplastic/myeloproliferative neoplasms share pathophysiologic features of decreased/deregulated myeloid maturation. Their diagnosis relies upon peripheral blood, bone marrow morphology, extended flow cytometry panels, detailed cytogenetic and molecular analysis tailored for each subtype, possible predisposing factors, and mimicking conditions. The overall genomic analysis provides a tool for refining risk stratification and selecting novel therapies.*

### INTRODUCTION

Myeloid neoplasms can manifest in various ways, including marrow failure with or without maturation arrest. Conditions like acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) fall into this category. Additionally, there are overlapping features of myeloid proliferation and defective maturation, termed Myelodysplastic/Myeloproliferative overlap syndromes (MDS/MPN).

In the patient care continuum, several critical stages and essential diagnostic tools are followed for initial diagnosis, risk stratification, response evaluation, and disease monitoring.

This chapter delves into the key clinicopathological aspects and comprehensive diagnostic approach of acute myeloid leukemia, myelodysplastic syndromes, and Myelodysplastic/Myeloproliferative neoplasms. It emphasizes the distinct diagnostic criteria, risk assessment, therapeutic strategies, and treatment response evaluation.

## **ACUTE MYELOID LEUKEMIA (AML)**

Acute myeloid leukemia (AML) stands as the most prevalent form of adult acute leukemia. Its incidence escalates with age, particularly in the context of myelodysplasia and therapy-related cases, with an average age of 70 years at diagnosis (Schneider et al., 2017).

AML typically manifests through marrow failure and rarely presents as a tumor mass—often solitary. This mass may serve as the initial or sole manifestation of de novo AML or a blast crisis stemming from an underlying myeloproliferative disorder, myelodysplastic syndrome, or AML relapse. Distinguishing it from a leucoerythroblastic reaction (characterized by few blasts) in myelofibrosis is of utmost importance (Bewersdorf & Abdel-Wahab, 2022).

In AML patients with hyperleukocytosis, certain emergencies warrant immediate attention. These include tumor lysis syndrome (TLS) and coagulopathy, particularly in cases like acute promyelocytic leukemia (APL). For APL, rapid treatment with all-trans retinoic acid (ATRA) is crucial—even before confirming the diagnosis and before any chemotherapy. If APL is ruled out, this treatment can be safely interrupted without adverse effects.

### **Clinicopathologic Features**

A diagrammatic representation of AML entities defined in the ICC and WHO5 (2022) classification is shown in 1. (Rato et al., 2022).

63 more pages are available in the full version of this document, which may be purchased using the "Add to Cart" button on the publisher's webpage:  
[www.igi-global.com/chapter/diagnostic-approach-to-myeloid-neoplasms-with-predominantly-ineffective-hematopoiesis/350011](http://www.igi-global.com/chapter/diagnostic-approach-to-myeloid-neoplasms-with-predominantly-ineffective-hematopoiesis/350011)

## Related Content

---

### Utilization of Bio-Imaging in Cancer Studies

Muneesh Kumar Barman, Manjita Srivastava, Meenakshi Singh, Khalid Umar Fakhri, Kailash Chand, Subash C. Sonkarand Prudhvilal Bhukya (2021). *Handbook of Research on Advancements in Cancer Therapeutics* (pp. 534-540).

[www.irma-international.org/chapter/utilization-of-bio-imaging-in-cancer-studies/267056](http://www.irma-international.org/chapter/utilization-of-bio-imaging-in-cancer-studies/267056)

### Dietary Management

(2020). *Diagnosing and Managing Hashimoto's Disease: Emerging Research and Opportunities* (pp. 215-240).

[www.irma-international.org/chapter/dietary-management/243796](http://www.irma-international.org/chapter/dietary-management/243796)

### Cannabinoid Efficacy for Developmental Epileptic Encephalopathy (DEE) Intractable Seizure Control: A Systematic Review of the Literature

Courtney R. Ackerand Rana R. Zeine (2023). *Medical Cannabis and the Effects of Cannabinoids on Fighting Cancer, Multiple Sclerosis, Epilepsy, Parkinson's, and Other Neurodegenerative Diseases* (pp. 76-102).

[www.irma-international.org/chapter/cannabinoid-efficacy-for-developmental-epileptic-encephalopathy-dee-intractable-seizure-control/320043](http://www.irma-international.org/chapter/cannabinoid-efficacy-for-developmental-epileptic-encephalopathy-dee-intractable-seizure-control/320043)

### Bone Marrow Sampling and Processing

(2024). *Principles and Approaches to Diagnostic Bone Marrow Examination* (pp. 31-49).

[www.irma-international.org/chapter/bone-marrow-sampling-and-processing/350003](http://www.irma-international.org/chapter/bone-marrow-sampling-and-processing/350003)

### Engagement in Health and Safety at the Workplace: A New Role for the Occupational Health Physician

Nicola Magnavita (2016). *Promoting Patient Engagement and Participation for Effective Healthcare Reform* (pp. 265-289).

[www.irma-international.org/chapter/engagement-in-health-and-safety-at-the-workplace/150356](http://www.irma-international.org/chapter/engagement-in-health-and-safety-at-the-workplace/150356)